SUN PHARMA | ALKEM LABORATORIES | SUN PHARMA/ ALKEM LABORATORIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 40.2 | 36.1 | 111.5% | View Chart |
P/BV | x | 6.5 | 6.3 | 102.9% | View Chart |
Dividend Yield | % | 0.8 | 1.1 | 72.4% |
SUN PHARMA ALKEM LABORATORIES |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SUN PHARMA Mar-23 |
ALKEM LABORATORIES Mar-23 |
SUN PHARMA/ ALKEM LABORATORIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,072 | 3,625 | 29.6% | |
Low | Rs | 790 | 2,835 | 27.9% | |
Sales per share (Unadj.) | Rs | 182.9 | 970.1 | 18.9% | |
Earnings per share (Unadj.) | Rs | 35.7 | 84.2 | 42.4% | |
Cash flow per share (Unadj.) | Rs | 46.2 | 110.2 | 42.0% | |
Dividends per share (Unadj.) | Rs | 11.50 | 50.00 | 23.0% | |
Avg Dividend yield | % | 1.2 | 1.5 | 79.8% | |
Book value per share (Unadj.) | Rs | 233.4 | 756.4 | 30.9% | |
Shares outstanding (eoy) | m | 2,399.34 | 119.57 | 2,006.6% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 5.1 | 3.3 | 152.8% | |
Avg P/E ratio | x | 26.1 | 38.4 | 68.0% | |
P/CF ratio (eoy) | x | 20.1 | 29.3 | 68.7% | |
Price / Book Value ratio | x | 4.0 | 4.3 | 93.4% | |
Dividend payout | % | 32.2 | 59.4 | 54.3% | |
Avg Mkt Cap | Rs m | 2,233,361 | 386,207 | 578.3% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 82,960 | 21,314 | 389.2% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 438,857 | 115,993 | 378.3% | |
Other income | Rs m | 8,199 | 2,161 | 379.4% | |
Total revenues | Rs m | 447,055 | 118,153 | 378.4% | |
Gross profit | Rs m | 112,900 | 15,065 | 749.4% | |
Depreciation | Rs m | 25,294 | 3,104 | 814.8% | |
Interest | Rs m | 1,720 | 1,074 | 160.2% | |
Profit before tax | Rs m | 94,084 | 13,048 | 721.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 8,476 | 2,980 | 284.5% | |
Profit after tax | Rs m | 85,608 | 10,068 | 850.3% | |
Gross profit margin | % | 25.7 | 13.0 | 198.1% | |
Effective tax rate | % | 9.0 | 22.8 | 39.4% | |
Net profit margin | % | 19.5 | 8.7 | 224.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 398,619 | 86,064 | 463.2% | |
Current liabilities | Rs m | 199,064 | 37,071 | 537.0% | |
Net working cap to sales | % | 45.5 | 42.2 | 107.7% | |
Current ratio | x | 2.0 | 2.3 | 86.3% | |
Inventory Days | Days | 147 | 33 | 451.1% | |
Debtors Days | Days | 95 | 67 | 141.8% | |
Net fixed assets | Rs m | 376,960 | 37,245 | 1,012.1% | |
Share capital | Rs m | 2,399 | 239 | 1,003.5% | |
"Free" reserves | Rs m | 557,555 | 90,208 | 618.1% | |
Net worth | Rs m | 559,954 | 90,447 | 619.1% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 775,794 | 124,541 | 622.9% | |
Interest coverage | x | 55.7 | 13.2 | 423.5% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.6 | 0.9 | 60.7% | |
Return on assets | % | 11.3 | 8.9 | 125.8% | |
Return on equity | % | 15.3 | 11.1 | 137.3% | |
Return on capital | % | 17.1 | 15.6 | 109.6% | |
Exports to sales | % | 0 | 14.6 | 0.0% | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | 16,916 | 0.0% | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 154,053 | 16,916 | 910.7% | |
Fx outflow | Rs m | 71,511 | 4,190 | 1,706.9% | |
Net fx | Rs m | 82,541 | 12,727 | 648.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 49,593 | 16,825 | 294.8% | |
From Investments | Rs m | -79,437 | 1,128 | -7,039.8% | |
From Financial Activity | Rs m | 23,761 | -17,608 | -134.9% | |
Net Cashflow | Rs m | 1,155 | 416 | 277.5% |
Indian Promoters | % | 54.5 | 56.7 | 96.0% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 36.5 | 24.7 | 147.7% | |
FIIs | % | 17.7 | 9.1 | 194.5% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 45.5 | 43.3 | 105.2% | |
Shareholders | 631,392 | 65,830 | 959.1% | ||
Pledged promoter(s) holding | % | 2.1 | 0.0 | - |
Compare SUN PHARMA With: CIPLA DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES SANOFI INDIA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Sun Pharma | ALKEM LABORATORIES | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 1.54% | 0.88% | 0.39% |
1-Month | -5.49% | -4.98% | 1.50% |
1-Year | 55.17% | 38.91% | 54.48% |
3-Year CAGR | 33.48% | 19.34% | 14.82% |
5-Year CAGR | 26.76% | 22.85% | 19.42% |
* Compound Annual Growth Rate
Here are more details on the Sun Pharma share price and the ALKEM LABORATORIES share price.
Moving on to shareholding structures...
The promoters of Sun Pharma hold a 54.5% stake in the company. In case of ALKEM LABORATORIES the stake stands at 56.7%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Sun Pharma and the shareholding pattern of ALKEM LABORATORIES.
Finally, a word on dividends...
In the most recent financial year, Sun Pharma paid a dividend of Rs 11.5 per share. This amounted to a Dividend Payout ratio of 32.2%.
ALKEM LABORATORIES paid Rs 50.0, and its dividend payout ratio stood at 59.4%.
You may visit here to review the dividend history of Sun Pharma, and the dividend history of ALKEM LABORATORIES.
For a sector overview, read our pharmaceuticals sector report.
Asian stocks fell on Thursday as disappointing earnings forecasts from Facebook parent Meta Platforms hammered tech shares, while the yen's slump past 155 per dollar.